A retrospective study assessing the acceleration effect of type I Helicobacter pylori infection on the progress of atrophic gastritis

Based on the antibody typing classification, Helicobacter pylori infection can be divided into type I H. pylori infection and type II H. pylori infection. To observe the effects of different H. pylori infection types on the distribution of histopathological characteristics and the levels of three items of serum gastric function (PG I, PG II, G-17). 1175 cases from October 2018 to February 2020 were collected with ratio 1:2. All patients were performed with 14C-Urea breath test (14C-UBT), H. pylori antibody typing classification, three items of serum gastric function detection, painless gastroscopy, pathological examination, etc. According to H. pylori antibody typing classification, patients were divided into three groups: type I H. pylori infection group, type II H. pylori infection group and control group. Significant difference existed among type I H. pylori infection group, type II H. pylori infection group and control group in inflammation and activity (χ2 = 165.43, 354.88, P all < 0.01). The proportion of three groups in OLGA staging had statistic difference (χ2 = 67.99, P all < 0.01); Compared with type II H. pylori infection group and control group, the level of pepsinogen I, pepsinogen II, gastrin17 in type I H. pylori infection group increased, and PG I/PG II ratio (PG I/PG II ratio, PGR) decreased, which was statistically significant (χ2 = 35.08, 166.24, 134.21, 141.19; P all < 0.01). Type I H. pylori infection worsened the severity of gastric mucosal inflammation and activity. H. pylori infection was prone to induce atrophy of gastric mucosa, while type I H. pylori infection played a key role in promoting the progress of atrophic gastritis and affected the level of serum gastric function. The study indicated that the eradication of H. pylori should be treated individually.

www.nature.com/scientificreports/ at a staircase increase 8 . Serological tests, including gastrin 17 (G-17) and pepsinogen (PG), could help to identify individuals at risk for AG. PG is an inactive precursor of pepsin in gastric juice and a special biological marker of gastric secretion. According to immunological activity and biochemical characteristics, PG can be divided into two categories: PGI and PGII, the former is mainly secreted by the chief cell and mucous neck cells, while the latter is secreted by fundus gland, cardiac glands, pyloric glands and Brunner's glands. Most of the synthetic PG is released into the gastric cavity, and only about 1% enter the blood circulation 9 . In ideal state, serum PG can accurately reflect the state of gastric mucosal lesion [10][11][12] . G-17 is an important gastrointestinal peptide hormone and produced in the antrum by G cells, which is correlated with the position and degree of gastric mucosal atrophy. When the synthesis of G-17 decreases, it could indicate the presence of AG in the antrum, while the presence of AG in the corpus can led to the increase of G-17 by the negative feedback of gastrin gastric acid axis 13 . This study aims to analyze the relationship between different types of H. pylori infection on the distribution of histopathological characteristics and the levels of three items of serum gastric function. As well as to provide a theoretical basis for the clinical individual eradication of H. pylori and a possible mechanism of type I H. pylori infection in the development of AG. Three items of serum gastric function detection. Fasting venous blood 2-3 ml was collected by vacuum tube, then the serum was separated. PGI, PGII, G-17 test kit (Fluorescence immunochromatographic assay) was provided by BIOHIT Healthcare (Hefei) Co., Ltd. Adding 80 μl serum to the test kit and placing in the Fluorescence immunoquantitative analyzer (HIT-91A) 15 min later. The results could be read by fast detection. The normal reference range of PGI, PGII, PGR and G-17 was 70-165 μg/l, 3-11 μg/l, 7-20 and 1-7 pmol/l, respectively.

Methods
Gastroscopy and pathological diagnosis. The diagnostic criteria for gastroscopy and pathology were based on Chinese consensus on chronic gastritis (2017, Shanghai) 14 . Five gastric mucosa biopsies were taken according to the standard, including two gastric antrum biopsies, two gastric body biopsies and one gastric corner biopsy. Histopathological evaluation was performed according to the Sydney system. Chronic inflammation, activity, atrophy and intestinal metaplasia were graded as absent (0); mild (1); moderate (2) and severe (3).
Statistical analysis. SPSS17.0 software was used to analyze the data. Continuous variables were described as mean (± standard deviationand), while categorical variables were described as percentages or frequencies, while categorical variables were described as percentages or frequencies. All data were tested for normal distribution by Shapiro-Wilk test. Kruskal-Wallis test was used to compare multiple quantitative variables, while chi-square test or Mann-Whitney U were used for pairwise comparison between groups. P value less than 0.05 was considered statistically significant. The relationship between different types of H. pylori infection with inflammation and activity. The proportion of different types of H. pylori infection in inflammation and activity was shown in Table 1.
In the distribution of inflammation degree, the proportion of moderate and severe inflammation in type I H. pylori infection group was higher than that in type II H. pylori infection group and control group (χ 2 = 165.43, P all < 0.01). In the distribution of activity degree, the proportion of mild and moderate activity in type I H. pylori infection group was higher than that in type II H. pylori infection group and control group (χ 2 = 176.22, P all < 0.01).

Relationship between different types of H. pylori infection in OLGA staging.
The histopathological evaluation of gastric mucosa biopsies was performed by updated Sydney system and the staging was expressed according to OLGA classification systems. In type I H. pylori infection group, only two inpatients with stage-3 OLGA staging, which were included in stage-2 OLGA staging for statistics facilitate. As it depicted in Table 2, the proportion of stage-2 in type I H. pylori infection group was higher than that in type II H. pylori infection group and control group, the difference had statistically significant (χ 2 = 44.34, P all < 0.01). Stage-0 in control group, type II H. pylori infection group and type I H. pylori infection group increased in turn, the difference was statistically significant (χ 2 = 67.99, P all < 0.01). Table 3

Discussion
It is a consensus that H. pylori infection is the cause of chronic gastritis, and H. pylori can cause sustained damage to gastric mucosa. H. pylori is viewed as a key cause in many diseases, such as chronic gastritis with atrophy and erosion, peptic ulcer, MALT lymphoma, gastric cancer and so on. AG is considered to be the outcome of H. pylori infection and is associated with a high risk of gastric cancer [15][16][17][18] . Although eradication of H. pylori can reduce the risk of gastric cancer in the general population, the risk of gastric cancer do exist, which is associated with the degree of AG and IM. Histological studies showed that there is no significant change in AG and IM during the 2 years after eradication of H. pylori, and AG and IM are significantly improved 10 years later 19 .
Eradicating of H. pylori is not always beneficial to some diseases, because it can lead to an increase in the level of gastric acid secretion, which may increase gastroesophageal reflux and ulceration of low dose aspirin. Therefore, individualized eradication of H. pylori is the best way 20 . OLGA classification and serum gastric function detection are optimal for early gastric cancer screening. A surveillance program including OLGA stage and serum gastric function status may facilitate early detection of gastric cancer 21 . ACG Clinical Guideline have demonstrated that patients over 60 years old and unexplained dyspepsia with no early warning symptoms are recommended for non endoscopic H. pylori tests, and those with positive results should be treated with eradication 22 . H. pylori infection is one of the most important factors causing atrophy and precancerous lesions. Recently, countries around the world are actively eradicating H. pylori infection to reduce the incidence rate of gastric cancer. However, only few countries can eradicate H. pylori infection for all, indicating that individualized treatment is the feasible strategy.
H. pylori has a variety of diagnostic methods 23,24 . The most non-invasive detection methods are 14 C-UBT and serum H. pylori antibody typing classification. There may be false positive and false negative results in 14 C-UBT. The combination of the two test results can accurately estimate H. pylori infection 25 . H. pylori antibody typing classification is mainly based on the expression of virulence protein CagA, VacA, Urease A and Urease B. CagA of H. pylori can accelerate the progress of gastric cancer and AG, in which tyrosine phosphorylated EPIYA modules play an important role in active gastritis, associating with the progression of diffuse-type of gastric cancer, especially in women 26 . The meta-analysis has summarized 33 studies and points that H. pylori CagA genotypes are associated with increased risk of AG, IM, and gastric cancer, especially IM and gastric cancer 27 . CagA positive H. pylori can downregulation of autophagy in the gastric mucosa and induce the increase of inflammatory factors and increase the degree of gastritis 28 . Through different types of H. pylori infection and histopathological characteristics analysis, it found that the degree of inflammation and activity caused by type I H. pylori was significantly higher than that caused by type II H. pylori. According to OLGA classification systems, histopathological evaluation results showed that type I H. pylori tended to a higher staging levels. Thus, it is speculated that H. pylori infection and its pathogenicity are closely related to the specific genes and proteins. The results suggested that different types of H. pylori infection had different characteristics, as well as explained that most of the patients with H. pylori infection did not have any symptoms.
In the gastric epithelial cells, CagA is transmitted through a unique type IV secretory system to the initial immune response, followed by a series of responses to recruit immune cells to form chronic gastritis, and serum CagA and VacA virulence proteins increase the risk of non cardia cancer, while the risk of low virulence protein of H. pylori is lower 29,30 . Serological detection of pepsinogen PG I, PGII, PGR and G-17, the epidemiological markers for gastric cancer risk investigation, has provided valuable information for the status of gastric mucosa 31 . This study showed that type I H. pylori infection could increase the level of serum PGI, PGII and G-17, possibly because the inflammatory mechanism. The study of H. pylori virulence factors were focused on the gene level, depicting that CagA and VacA gene positive samples have strong correlation with AG and IM, and can better predict AG and IM 32,33 . Some studies have found that the invasion ability of H. pylori infection is associated with the middle region of the vacA gene 34,35 . This result suggested that different types of H. pylori infection might be related to the size of the invasiveness. According to the different secretory sites of PGI and PGII in the stomach, it is speculated that type I H. pylori infection could increase the secretion of serum PG in the whole stomach and duodenum region. The infection of type I H. pylori infection might accelerate the progress of atrophic gastritis due to the increase the invasion of gastric mucosa and the level of serum gastric function through unique inflammatory mechanisms.
In conclusion, different types of H. pylori had different characteristics. Through the analysis of histopathological characteristics and serum gastric function, it is confirmed that type I H. pylori infection played a key role in worsening the progress of atrophic gastritis, while the role of type II H. pylori infection is relatively weak. Thus, the clinical application of H. pylori eradication should be differentiated based on the H. pylori antibody typing classification and individualizing eradication of H. pylori can benefit more people.